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Alpha-synuclein (Snca) plays a major role in Parkinson disease (PD). Circulating anti-Snca
antibodies has been described in PD patients and healthy controls, but they have been
poorly characterized. This study was designed to assess the prevalence of anti-Snca reac-
tivity in human subjects carrying the LRRK2 mutation, idiopathic PD (iPD) patients, and
healthy controls and to map the epitopes of the anti-Snca antibodies. Antibodies to Snca
were detected by ELISA and immunoblotting using purified recombinant Snca in plasma
from individuals carrying LRRK2 mutations (104), iPD patients (59), and healthy controls
(83). Epitopes of antibodies were mapped using recombinant protein constructs compris-
ing different regions of Snca. Clear positive anti-Snca reactivity showed no correlation with
age, sex, years of evolution, or the disability scores for PD patients and anti-Snca reactivity
was not prevalent in human patients with other neurological or autoimmune diseases.Thir-
teen of the positive individuals were carriers of LRRK2 mutations either non-manifesting
(8 out 49 screened) or manifesting (5 positive out 55), three positive (out of 59) were iPD
patients, and five positive (out of 83) were healthy controls. Epitope mapping showed that
antibodies against the N-terminal (a.a. 1–60) or C-terminal (a.a. 109–140) regions of Snca
predominate in LRRK2 mutation carriers and iPD patients, being N122 a critical amino acid
for recognition by the anti-C-terminal directed antibodies. Anti-Snca circulating antibodies
seem to cluster within families carrying the LRRK2 mutation indicating possible genetic
or common environmental factors in the generation of anti-Snca antibodies. These results
suggest that case-controls’ studies are insufficient and further studies in family cohorts of
patients and healthy controls should be undertaken, to progress in the understanding of
the possible relationship of anti-Snca antibodies and PD pathology.
Keywords: alpha-synuclein, human antibodies, ELISA, immunoblot, epitope mapping, LRRK2 mutation, Parkinson
disease
INTRODUCTION
Parkinson disease (PD) and other synucleinopathies (dementia
with Lewy bodies and multiple system atrophy) are characterized
pathologically by proteinaceous inclusions commonly described
as Lewy pathology in postmortem brain tissue samples (Goedert,
2001). Alpha-synuclein (Snca) is the major protein constituent of
Lewy bodies (Spillantini et al., 1998). Snca is mainly a cytoplasmic
protein, but it has been shown to be secreted by exocytosis and is
also present in exosomes (Lee et al., 2005; Emmanouilidou et al.,
2010; Jang et al., 2010; Pan-Montojo et al., 2012). Snca has been
found in cerebrospinal fluid (CSF) and plasma and its concentra-
tion in these fluids has been suggested as a possible biomarker for
PD (Parnetti et al., 2013), even though there are substantial dis-
crepancies between the results reported in different studies (Lee
et al., 2006; Li et al., 2007; Duran et al., 2010; Shi et al., 2010;
Mollenhauer et al., 2011; Park et al., 2011; Foulds et al., 2012;
Wennstrom et al., 2013). In this context, recent measurements
of clearance of Snca in CSF under steady-state conditions in PD
patients and PD animal models show that there is no change in
the clearance of Snca in the CSF respect to the corresponding con-
trols (Fanara et al., 2012). Further interest in extracellular Snca
is due to data showing that extracellular Snca in an aggregated
form may have a potential role in the spreading of the PD pathol-
ogy, as suggested by the finding of Lewy bodies in fetal neurons
transplanted to PD patients (Kordower et al., 2008; Li et al., 2008;
Mendez et al., 2008) and the spreading of aggregation of neuronal
endogenous Snca in response to the addition (cells) or injection
(animals) of aggregated fibrillar Snca (Luk et al., 2009, 2012a,b;
Volpicelli-Daley et al., 2011). The extracellular behavior of Snca
is also part of the rationale for an immunological intervention as
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possible treatment for PD. Active (Masliah et al., 2005) or passive
immunization (Masliah et al., 2011) against Snca has been shown
to be effective in prevention of the pathology observed in mice
models overexpressing human Snca.
The study of anti-Snca antibodies, as a possible biomarker for
PD, has also received considerable attention. The initial study of
the presence of antibodies against Snca in human subjects was
undertaken because commercially available anti-latent protein 1
EBV antibodies cross-reacted with Snca (Woulfe et al., 2000) and
later the same authors reported no difference in prevalence of anti-
Snca reactivity between idiopathic PD (iPD) patients and healthy
controls (Woulfe et al., 2002). Afterwards, multi-epitopic Snca
antibodies were found in patients from families with uncharacter-
ized familial forms of PD, but its frequency was not significantly
higher in iPD patients with respect to healthy controls (Papachroni
et al., 2007). Later studies have shown that there is no signifi-
cant difference in the presence of anti-Snca antibodies between
iPD patients and healthy controls (Smith et al., 2012; Besong-
Agbo et al., 2013), while other studies found significant differences,
with higher frequency in iPD patients (Yanamandra et al., 2011).
Nevertheless, the human anti-Snca antibodies have been poorly
characterized.
The present study was designed to evaluate the presence of
antibodies against Snca in subjects with dominant LRRK2 muta-
tions, asymptomatic (non-manifesting carriers) and symptomatic
(manifesting carriers), iPD patients (manifesting non-carriers),
and healthy controls, all of them reside in the Basque country
(Spain). We took advantage of the fact that LRRK2 mutation,
a well known cause of familial PD, is responsible for 46% of
familial PD and for 2.5% of sporadic PD in the PD popula-
tion of Basque ascent (Ruiz-Martinez et al., 2010). Sera form
patients with other neurological or autoimmune diseases were
also evaluated for the presence of anti-Snca antibodies, as a way
to study disease specificity. Finally, we also report the mapping
of the major epitopes of the anti-Snca antibodies present in non-
manifesting and manifesting LRRK2 carriers, iPD patients, and
healthy controls.
MATERIALS AND METHODS
PATIENTS
Plasma from 49 asymptomatic (non-manifesting carriers)
LRRK2 mutation carriers (Asymp LRRK2) and 55 symptomatic
(manifesting carriers) LRRK2 mutation carriers (Symp LRRK2
PD) belong to 38 different families, 55 iPD patients (manifest-
ing non-carriers), and 83 healthy controls were all recruited from
the Movement Disorders Unit (MDUD) of the Hospital Universi-
tario Donostia, San Sebastian, Spain. All iPD patients and healthy
controls were negative for LRRK2 mutations. These patients and
controls were mainly from the Basque region of Spain, where the
prevalence of LRRK2 mutation is significantly higher than in other
Spanish regions. Information recorded for each subject included
age, gender, time of symptoms onset, and date of first diagno-
sis. Patients with PD fulfilled the diagnostic criteria of PD (Gelb
et al., 1999) and Parkinson’s disability scores using Unified Parkin-
son’s Disease Rating Scale (UPDRS-III) (Goetz et al., 2007) and
the Hoehn and Yahr (H&Y) scale (Hoehn and Yahr, 2001) were
also measured. Demographic data of patients and healthy con-
trols are summarized in Table 1. We also analyzed sera from 17
patients with progressive supranuclear palsy (PSP) that were resi-
dents in the Basque country, 43 patients with Alzheimer’s disease
(AD) provided by Dr. Ana Frank, IdiPaz, Department of Neurol-
ogy, La Paz University Hospital, Madrid, Spain, 45 patients with
diagnosis of relapsing–remitting MS derived from our own pre-
vious studies (Mayo et al., 2002) and their demographic data are
summarized in Table S1 in Supplementary Material. Table S1 in
Supplementary Material also presents the demographical data of
other patients whose sera were also screened for anti-Snca antibod-
ies: 36 patients with diagnosis of primary biliary cirrhosis (PBC),
25 patients with diagnosis of systemic lupus erythematosus (SLE),
15 patients with diagnosis of Sjögren syndrome, and 39 healthy
controls. Patients and healthy controls summarized in Table S1
in Supplementary Material were resident in the area of Madrid,
Spain and were provided by Dr. Rita Alvarez Do-Forno, IdiPaz,
Department of Immunology, La Paz University Hospital, Madrid.
The current investigation was approved by the Ethical Committee
Table 1 | Demographical characteristics of patients and healthy control subjects used for the screening of antibodies against Snca.
Characteristics Condition
Asymptomatic
LRRK2 carriers
Symptomatic
LRRK2 carriers
Idiopathic PD Healthy control
subjects
Age (mean±SD) 51.18±11.3 68.37±10.23 67.81±9.98 61.4±14.7
Sex (M/F) 23/26 23/32 34/25 38/45
Number of patients with LRRK2 mutation R1441G/G2019S 43/6 39/16 NA NA
Age onset NA 61±9 62±12 NA
Years evolution up to date of testing (mean±SD) NA 13±11 12±8.7 NA
UDPRS (mean±SD) NA 26±13 28±12 NA
Hoehn and Yahr score (mean±SD) NA 2.25±0.88 2.44±0.80 NA
Clear-cut positive anti-Snca/total screened (OD≥0.5 by
endpoint ELISA and titer by immunoblot ≥1/200)
8/49 5/55 3/59 5/83
NA, not applied.
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of the participating hospitals and conducted according to the Dec-
laration of Helsinki principles and informed consent was obtained
from all subjects.
CLONING, BACTERIAL EXPRESSION, AND PURIFICATION OF
RECOMBINANT PROTEINS
Recombinant wild type (wt) Snca and the point mutants, A30P,
E46K, and A53T were purified as described (Martin-Clemente
et al., 2004; Alvarez-Castelao and Castano, 2011). Because of the
results obtained with this initial preparation, we need to add one
further step of purification of the recombinant Snca by RP-HPLC
on a Vydac-C18 column equilibrated in 0.1% TFA and elution
with a linear gradient (0–40% acetonitrile in 0.1% TFA). The frac-
tions containing Snca were pooled lyophilized and store frozen at
−70°C until used. Deletion constructs, Snca stop109, His-tag Snca,
His-tag 1–60, and His-tag 61–140 hSnca wt, were purified from
induced BL-21 bacterial cultures as described (Alvarez-Castelao
and Castano, 2011; Alvarez-Castelao et al., 2014).
ELISA ANDWESTERN IMMUNOBLOT ANALYSIS
To detect anti-Snca antibodies, 100µL of recombinant Snca
(10µg/mL) in 0.1 M Na2CO3 was coated overnight on 96-well
ELISA microtitration plates (Maxisorp; Nunc, Roskilde, Den-
mark). After three washes with 250µL of TTBS (0.1% Tween 20
in 1×TBS: 50 mM Tris–Cl pH 7.4, 150 mM NaCl), the wells were
blocked with 150µL of TTBS containing 3% BSA (Sigma A3803)
and incubated for 2 h at 37°C to avoid non-specific binding. After
three washes with 250µL of TTBS, the plasma or serum samples
(100µL, starting from a 1:100 dilution in TTBS with 1% BSA)
were placed into the wells and incubated for 60 min at room tem-
perature (RT). After four washes with 250µL of TTBS, 100µL of
secondary antibody goat anti-human IgG (Sigma, 1:2000) diluted
in TTBS+ 1% BSA was added to each well and incubated for 1 h at
RT. Wells were washed four times with TTBS and 100µL of devel-
oping reagent containing p-nitrophenyl-phosphate was added.
Plates were incubated at RT and kinetic readings were obtained
in a microplate reader (Infinity M1000, Tecan) at 405 nm. End
point values were obtained after 1 h incubation at RT. Accuracy of
the ELISA assay was determined by 1:2 dilutions with a negative
sample of plasma/sera from five different patients with different
levels of reactivity. Intra-assay precision was determined by testing
10 replicates of each (low, medium, and high) range of reactivity
and the CV calculated for each of the concentration range from
their respective average and SD. Inter-assay precision was deter-
mined by testing three (1:100) dilutions of each (low, medium
and high) reactivity range and testing at two different occasions,
1 week apart, the CV was calculated from their respective average
and SD. No difference was found by using sera or plasma in the
detection of anti-Snca antibodies.
For immunoblot analysis, 1–2µg of purified recombinant
proteins were separated on 14 or 16% SDS-PAGE. Gels were
transferred to nitrocellulose or PVDF for immunoblotting. Mem-
branes were blocked overnight at 4°C with blocking buffer
TTBS with 3% BSA. The membranes were incubated for 2 h
at RT with plasma or sera from human subjects (unless oth-
erwise indicated) at 1:100 dilution. After washing three times
with TTBS (10 min each), the blots were incubated with alkaline
phosphatase labeled goat anti-human IgG antibodies (Sigma) at
1:2000 dilution for 1 h at RT, washed three times (10 min each)
with TTBS and developed with nitro-blue tetrazolium and 5-
bromo-4-chloro-3′-indolyphosphate, as described (Mayo et al.,
2002).
ANTIBODY-AFFINITY PURIFICATION
Purified recombinant Snca was subjected to continuous 14% SDS-
PAGE and western blotted. The horizontal strip containing Snca
was excised, blocked with TTBS containing 3% BSA, and incu-
bated for 3 h at RT with 0.4 mL of patient serum prepared in the
same buffer. The membrane was then washed with TTBS three
times (10 min each) and the bound antibodies were eluted by
incubation with 0.2 M Gly, pH 2.4. The solution containing the
eluted antibodies was immediately neutralized with 1 M Tris–Cl
pH 7.4 and diluted threefold with TTBS. Finally, the neutralized
and diluted solution was used for further analysis.
MICE SAMPLES
Snca (−/−) knock-out mice, their corresponding control wt mice
(+/+), and transgenic mice for human wt Snca under the con-
trol of the tyrosine hydroxylase (TH) promoter were provided by
Dr. Isabel Fariñas, Facultad de Biología, Universidad de Valencia
and have been described previously (Abeliovich et al., 2000; Perez-
Sanchez et al., 2010). Animals were housed and sacrificed following
the local legislation in agreement with the European Union guide-
lines (86/609/EEC and 2003/65/EC, European Council Directives).
Mice were anesthetized and whole brains were removed, fresh
brains were subjected to dissection, cut into coronal sections and
immediately frozen in liquid nitrogen and stored at −80°C until
further processing. Crude extracts were obtained by homoge-
nization of the brain sections in TTBS (1/4 weight/volume) and
centrifuged at 14 ,000×g for 30 min at 4°C to remove insoluble
materials. The extracts were loaded (50µg of total protein) onto
14% SDS-PAGE, western blotted, and processed for immunoblot-
ting as described above. Anti-tubulin (Sigma) antibodies were used
as control of protein loading.
STATISTICAL METHODS
Statistical analysis was performed using the SPSS 15.0 software
package (SPSS Inc., Chicago, IL, USA). The statistical differ-
ence in Snca antibodies (ELISA endpoint OD readings) between
different groups of patients and healthy controls was evaluated
by Mann–Whitney U -test. The prevalence of positivity between
patients groups and healthy controls was evaluated by Pearson’s
chi-squared test (χ2).
RESULTS
ELISA AND IMMUNOBLOT ANALYSIS OF ANTIBODIES AGAINST Snca
Forty-nine non-manifesting LRRK2 mutation carriers (Asymp
LRRK2), 55 manifesting LRRK2 mutation carriers (Symp LRRK2),
59 idiopathic iPD patients, and 83 healthy controls were included
in the initial screening for anti-Snca antibodies, their demo-
graphic data are summarized in Table 1. The presence of Snca
antibodies was determined by ELISA using purified recombinant
Snca obtained after RP-HPLC purification step. For ELISA val-
idation, accuracy and intra- and inter-assay precision tests were
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 169 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alvarez-Castelao et al. Epitope mapping of human alpha-synuclein antibodies
performed. The accuracy of the assay was determined by 1:2
dilutions of plasma/sera from five different patients and a neg-
ative sample [end point OD 0.12± 0.05 (SD), n= 30 independent
assays)] that was not significantly different from the background
reading obtained without addition of primary antibodies. The
expected values were estimated as half of the values obtained with
the undiluted sample, accuracy was then calculated as percent
(expected/obtained values× 100), and the results are summarized
in Table S2 in Supplementary Material. The intra-assay precision
(within-run) was determined by repeating 10 times the assay of
samples from patients with different levels of reactivity and the
calculated CV values are presented in Table S3 in Supplemen-
tary Material. Finally, the inter-assay precision was determined
by triplicate analysis of samples with different levels of reactivity
in two different occasions, 1 week apart, and the results are pre-
sented in Table S4 in Supplementary Material. The results obtained
validated the ELISA method used for the determination of the
presence of Snca antibodies, as we obtained a good recovery (92–
108%) indicating that the assay was accurate and with a good
intra- and inter-assay reproducibility (CV< 15%) indicating a
good precision. Endpoint ELISA titers were estimated by serial
dilutions and determined as the highest dilution, which gave an
OD endpoint reading >0.25 OD units, the titers obtained ranged
from 1/100 to 1/1000. Comparison of endpoint ELISA OD read-
ings (Figure 1A) of the four groups under study (patients and
healthy controls) by Mann–WhitneyU -test showed that the differ-
ences were not significant. Furthermore, no correlation was found
between Snca reactivity and either age, sex, age of onset, years of
disease evolution, the H&Y score, or the UPDRS.
Analysis of the Snca reactivity by immunoblot was also per-
formed, titers by immunoblot also ranged from 1/100 to 1/1000.
From the combined methods of antibody detection (ELISA and
Immunoblot), we could assign “clear-cut” presence of antibod-
ies against Snca (OD≥ 0.5 by endpoint ELISA and titer by
immunoblot≥1/200) in 8 out 49 non-manifesting LRRK2 carriers,
5 out 55 manifesting LRRK2 carriers, 3 out 59 iPD patients, and 5
out 83 healthy controls. Examples of reactivity by immunoblot
analysis are presented in Figure 1B. All those individuals that
were positive against wt Snca also recognized A30P, E46K, and
A53T Snca missense point mutants; an example is shown in
Figure 1C. Considering only those “clear-cut” set of positive indi-
viduals, the prevalence of antibodies against Snca was higher
in non-manifesting LRRK2 carriers (Asymp LRRK2) than in
healthy controls (χ2= 3.683, p= 0.05) or than in iPD patients
(χ2= 3.698, p= 0.05). All other possible comparisons (Asymp
LRRK2 vs. Symp LRRK2 patients, Symp LRRK2 PD respect to iPD
or healthy controls and iPD patients respect to healthy controls)
were not significantly different.
To determine disease specificity, sera from patients with other
neurological and autoimmune diseases were screened for the pres-
ence of anti-Snca antibodies by immunoblot analysis at 1/200
dilution. The prevalence of Snca antibodies was rare (Table S1
in Supplementary Material) in samples from patients with clinical
diagnosis of AD, PSP, MS, PBC, SLE, and Sjögren syndrome. Sera
of healthy controls from a different geographical region (Madrid,
Spain) were also screened, because we were surprised with the
number of “clear-cut” positive individuals found in the healthy
FIGURE 1 | Anti-alpha-synuclein IgG antibodies levels and
representative immunoblot analysis of Snca reactivity in patients and
healthy controls. (A) A box plot of the results of endpoint readings of
ELISA assays for antibodies against alpha-synuclein (Snca). Symbols are as
follows: the median, line through the box; upper (q3) and lower (q1)
quartiles, upper and lower borders of box, respectively; most extreme
non-outlier values, vertical lines; and outliers, maximum and minimum
values are represented by dashes for each group of individuals; healthy
controls, none manifesting (Asymp) and manifesting (Symp) carriers of the
LRRK2 mutation, and idiopathic PD (iPD), as indicated. Differences were
not significant by Mann–Whitney U -test. (B) Continuous gels were loaded
with purified recombinant Snca and western blotted; and membranes were
cut into vertical strips (Ponceau staining) for testing several samples.
Individual strips were incubated with plasma at 1/100 dilution. The images
show representative results obtained with samples from healthy controls,
negative (−) or positive (+), Asymp and Symp carriers of the LRRK2
mutation, and iPD patients that were all positive for the presence of
anti-Snca antibodies. (C) An example of a positive sample tested against
purified recombinant Snca wild type (wt) and the missense mutants A30P,
E46K, and A53T.
control group from the Basque country and the results obtained
(1 positive out 39, Table S1 in Supplementary Material) did not dif-
fer significantly respect to the healthy controls obtained from the
Basque country. These results indicate that “clear-cut” anti-Snca
reactivity is not very prevalent and seems not to be associated with
other neurological or autoimmune diseases.
EPITOPE MAPPING OF ANTI-Snca ANTIBODIES
Next step was to map the epitopes of the human anti-Snca anti-
bodies using different recombinant Snca constructs by western
immunoblotting. To that end, we subcloned and expressed in bac-
teria three fragments of Snca corresponding to the N-terminal
region (His-Snca a.a. 1–60), to the C-terminal region (His-Snca
a.a. 61–140), and a Snca with a stop codon at position 109
(Snca a.a. 1–108). Those recombinant proteins were purified and
tested together with Snca full length to map the epitopes of the
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human anti-Snca antibodies; the results obtained are exemplified
in Figure 2A. Seven out of the 21 positive individuals had anti-Snca
antibodies whose main epitope must be located at the N-terminal
region of Snca (a.a. 1–60), as they reacted with protein constructs
Snca 1–60 and 1–108, but not with Snca 61–140. Three out those
21 had antibodies whose main epitope must be located in the cen-
tral region of Snca between positions 61 and 108, as they reacted
with Snca constructs 1–108 and 61–140, but not with Snca 1–60.
Finally, 11 of those 21 positive individuals had antibodies whose
main epitope was located at the C-terminal region of Snca (a.a.
109–140) only reacting with protein construct 61–140, but not
with Snca 1–60 or 1–108. The frequency of positive reactivity for
each of the Snca protein regions as defined above is presented in
Figure 2B and summarized in Table 2. There was no apparent epi-
tope specificity that could discriminate between the four groups of
individuals under analysis. Nevertheless there are clear tendencies,
N-terminal (1–60) and C-terminal (109–140) specific antibodies
(six times more frequent than anti-central Snca region antibodies,
Table 2) were present mostly in carriers of the LRRK2 muta-
tion (either manifesting or non-manifesting) and iPD patients,
while antibodies against the N-terminal region (a.a. 1–60) were
not found within positive healthy controls. Antibodies directed
against the central region of Snca (a.a. 61–108) were only found
in one manifesting LRRK2 carrier and in two healthy controls.
The anti-Snca positive individuals carrying the LRRK2 mutation
were analyzed for possible clustering in certain families (we have
samples from a total of 38 different families). Family 1 with 21
members of the family screened, gave five positive individuals,
four non-manifesting, and one manifesting LRRK2 carriers, and
the epitopes recognized were either located at the N-terminal (a.a.
1–60) or C-terminal (109–140) regions of Snca (Table 2). Family
4 with 5 members of the family screened gave two positive, with
epitopes again located at the N-terminal or C-terminal regions of
Snca (Table 2). The rest of positive individuals were from different
families, one out of a total of six screened from family 3, one out
of two members of family 6, one out of six of family 13, one out
of two of family 4, and one out one of family 20.
A more refined epitope mapping was obtained for those human
anti-Snca antibodies directed against the C-terminal region of
Snca (a.a. 109–140) by the serendipitous isolation of a Snca mutant
that harbors a single missense mutation N122S obtained as an
artifact of a PCR amplification. All individuals with anti-Snca anti-
bodies whose epitope was not located at the C-terminus recognize
both Snca wt and the full-length missense N122S mutant (data
not shown). In contrast, two types of circulating antibodies were
found in the 11 individuals whose main epitope was located at
the C-terminus (a.a. 109–140). Two individuals had antibodies
that recognized both Snca wt and N122S (Figure 3A), In contrast,
nine individuals have antibodies that recognize Snca wt, but not
Snca N122S (Figure 3B). These results indicated that amino acids
around N122 constitute a major determinant for recognition by
circulating antibodies recognizing the C-terminal region of Snca.
AFFINITY-PURIFIED HUMAN ANTI-Snca ANTIBODIES
To further characterize the presence of antibodies against Snca,
we performed affinity-purification of the specific antibodies using
human recombinant Snca. The eluted antibodies were tested by
FIGURE 2 | Epitope mapping of anti-Snca human antibodies. (A)The
blots of the different purified Snca constructs (Ponceau) used to characterize
the epitopes of anti-Snca antibodies and examples of the different types of
results obtained. Plasma that contained antibodies that recognize His-Snca
1–60, Snca full length and Snca 1–108 (Stop 109), but not His-Snca 61–140
and accordingly, their main epitope must be located at the N-terminus of
Snca (a.a. 1–60). Plasma that contained antibodies that recognize His-Snca
61–140, Snca full length, but not His-Snca 1–60 and Snca 1–108 (Stop 109)
and as a consequence, their epitope must be located at the C-terminal
region of Snca (a.a. 109–140). Finally, plasma that contained antibodies that
recognize His-Snca 61–140, Snca full length and Snca 1–108 (Stop 109), but
not His-Snca 1–60 and accordingly their main epitope must be located at
the central region of Snca (a.a 61–108). (B) Graph showing the number of
individuals scoring positive for the indicated regions of Snca that were
found within healthy controls, iPD, and manifesting LRRK2 carriers
(SympLRRK2) and non-manifesting LRRK2 carriers (Asymp LRRK2).
immunoblot against 1µg of human recombinant Snca and all
were positive, as expected. If those eluted antibodies have enough
specificity and affinity for Snca, there should be able to detect Snca
in crude brain extracts from wt mice and show no reactivity with
brain extracts obtained from Snca null mice. In fact, as shown
in Figure 4, patient 08–411, a non-manifesting R1441G LRRK2
carrier, had antibodies whose main epitope was located at the
N-terminal region (a.a. 1–60) of Snca (Figure 4A). Both the orig-
inal diluted plasma and the affinity-purified anti-Snca antibodies
were able to detect Snca in the extracts of brain from wt and hSnca
TH-driven transgenic mice, and the protein band detected was not
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Table 2 | Epitopes of positive anti-Snca antibodies.
Condition Epitope 1–60 Epitope 61–108 Epitope 109–140
No. positive subjects,
family ID No. (mutation)
No. positive subjects,
family ID No. (mutation)
No. positive subjects,
family ID No. (mutation)
Asymptomatic LRRK2 carriers 2, Fam. 1 (R1441G) 0 2, Fam. 1 (R1441G)
1, Fam. 3 (G2019S) 1, Fam. 4 (R1441G)
1, Fam. 4 (R1441G) 1, Fam. 6 (R1441G)
Symptomatic LRRK2 carriers 1, Fam. 14 (R1441G) 1, Fam. 8 (R1441G) 1, Fam. 1 (R1441G)
1, Fam. 20 (R1441G) 1, Fam. 13 (R1441G)
Idiopathic PD 1 (NA) 0 2 (NA)
Healthy controls 0 (NA) 2 (NA) 3 (NA)
% Positive/total positive 33.3 14.3 52.4
% Familial LRRK2 positive/total positive 28.6 4.7 28.6
% iPD positive/total positive 4.7 0 9.5
% Positive healthy controls/total positive 0 9.5 14.3
NA, not applied.
FIGURE 3 | Fine mapping of human anti-Snca antibodies directed
against the C-terminal region of Snca (a.a. 109–140). (A) An example of
the reactivity of human anti-Snca antibodies directed against the C-terminal
region of Snca (a.a. 61–140) that also recognized Snca full length and the
single point mutant Snca N122S. (B) An example of the reactivity of human
anti-Snca antibodies directed against the C-terminal region of Snca (a.a.
61–140) that recognized Snca full length, but not the single point mutant
Snca N122S. (C) Graph showing the total number of individuals scoring
positive for antibodies against the C-terminal region of Snca and those that
were negative for the N122S missense mutant within the different groups
under study: healthy controls, iPD, and manifesting LRRK2 carriers
(SympLRRK2) and non-manifesting LRRK2 carriers (Asymp LRRK2).
found in brain extracts from Snca null mice (Figure 4B). These
stringent test conditions were not met by any other of the original
plasma/sera or affinity-purified antibodies, whose reaction with
brain extracts was not significantly different from background
FIGURE 4 | Immunoreactivity of human anti-Snca antibodies against
brain extracts from wild type (wt), Snca knock-out, and human Snca
transgenic mice. Panels show the results obtained with the serum from
patient 08–41, an asymptomatic LRRK2 patient. (A) Immunoblot analysis at
1/100 dilution against recombinant His-tag 1–60, His-tag 61–140, full length,
and 1–108 (Stop 109) Snca showing that the main epitope was located at
the N-terminal region of Snca (a.a. 1–60). (B) Immunoblot analysis of total
serum upper part (08–411, 1/100 dilution) and affinity-purified anti-Snca
antibodies [08–411 affinity-purified (A. P.) corresponding to 1/500 dilution of
the original sample] against brain extracts prepared from wt, Snca
knock-out, and human TH-Snca transgenic mice (Tg+).
reaction obtained with human plasma/sera that were negative for
anti-Snca antibodies. These results clearly pointed out that most
part of the human anti-Snca antibodies detected in patients and
healthy controls are low affinity antibodies.
DISCUSSION
At the beginning of this study, we used recombinant purified Snca
obtained as described previously (Martin-Clemente et al., 2004;
Alvarez-Castelao and Castano, 2011) that was 95% homogenous
by Coomassie blue staining. This protein preparation gave consis-
tent results by ELISA, but when we checked some of the ELISA
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 169 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alvarez-Castelao et al. Epitope mapping of human alpha-synuclein antibodies
positive samples by immunoblot, we found that some of those
clearly positive by ELISA did not recognize the Snca protein itself,
but minor, likely E. coli, protein contaminants that were not obvi-
ous by Coomassie blue staining. These inconsistent results made
us to introduce a further step of purification of Snca by RP-HPLC,
rending a preparation of Snca close to 98% homogenous. The RP-
HPLC Snca preparation gave consistent results by both techniques
ELISA and immunoblot. Accordingly, we adopt the RP-HPLC
step of Snca purification for all the studies reported here. The
results we have obtained on the prevalence of anti-Snca antibod-
ies in our case (iPD) and control (healthy subjects) study are in
agreement with those published previously (Woulfe et al., 2002;
Papachroni et al., 2007; Smith et al., 2012; Besong-Agbo et al.,
2013) showing that there is no significant difference in the preva-
lence of anti-Snca antibodies between iPD patients and healthy
controls. Furthermore, neither there is a higher prevalence of
anti-Snca antibodies in non-manifesting (Asymp) or manifesting
(Symp) LRRK2 carriers than in iPD patients or healthy controls
when cut-off for anti-Snca positive reaction was established at
OD≥ 0.3 by endpoint ELISA and titer by immunoblot ≥1/100.
When more stringent cut-off conditions were used for catego-
rization of positive reactivity (OD≥ 0.5 by endpoint ELISA and
titer by immunoblot ≥1/200), significant difference in the preva-
lence of anti-Snca antibodies was found between non-manifesting
(Asymp) LRRK2 patients and iPD patients or healthy controls.
Under those restricted categorization of positive reactivity, we have
also shown that anti-Snca antibodies are not significantly associ-
ated with other neurological or autoimmune diseases (see Table
S1 in Supplementary Material), indicating some degree of disease
specificity.
The anti-Snca antibodies detected were of the IgG class indi-
cating that they are clearly distinct from the natural occurring and
self-reactive autoantibodies commonly found in humans and ani-
mals, even in mice reared under germ-free condition, as they are
mainly of the IgM class and polyreactive (Mannoor et al., 2013).
Nevertheless, most of the anti-Snca IgG antibodies detected have
low affinity for the antigen, as they were able to detect 1µg of
recombinant Snca, but unable to detect specifically the amount
of Snca present in crude mouse brain extract (approximately
50 ng of Snca is present in 50µg of total brain protein), excep-
tion made for one of the positive non-manifesting LRRK2 carriers
(see Figure 3).
In spite of the low affinity of human anti-Snca antibodies, we
have been able to clearly map the epitopes recognized by the
human circulating antibodies using recombinant Snca protein
constructs. It is noteworthy the absence of anti-N-terminal (a.a.
1–60) antibodies in healthy controls and the predominance of anti-
N and C-terminal antibodies in LRRK2 carriers and iPD patients.
We have also found clustering of anti-Snca reactivity within fam-
ilies for individuals carrying the LRRK2 mutation. Actually, 5 out
of the 13 positive anti-Snca individuals that are LRRK2 carriers
belong to family 1 (Table 2) and 1 of the healthy controls that had
anti-Snca antibodies was a non-manifesting, non-carrier member
of family 1 that has also anti-C-terminal (a.a. 109–140) anti-Snca
antibodies. The main epitope of those anti-C-terminal antibodies
from LRRK2 carriers seems to be located around amino acid N122.
Unfortunately, we do not have samples from other family mem-
bers of iPD patients or healthy controls (not typically considered in
case-control studies); as a consequence, we could not check family
clustering in those groups. These results extend a previous report
that describes the presence of anti-Snca antibodies in familial,
while genetically uncharacterized, forms of PD (Papachroni et al.,
2007). Taken together, the interpretation of these results clearly
point to a possible genetic (or common environmental) compo-
nent for the formation of anti-Snca antibodies that may also affect
the processing and/or presentation of Snca derived peptides to
immune competent cells.
We have also tried to delineate if anti-Snca reactivity may have
characteristics of an autoimmune response, as several autoim-
mune diseases (or only the presence of autoantibodies) also show
familial aggregation where more than one member of a nuclear
family has a single autoimmune disease (Cardenas-Roldan et al.,
2013). Changes in antibody titer, appearance of epitope spread-
ing, and/or conversion from negative to positive reactivity (or the
opposite) along with time in different individuals would be indica-
tions of an “on-going” active immune response that could be due
to an autoimmune (loss of tolerance) mechanism. We have limited
follow-up samples of the patients carrying the LRRK2 mutation,
and no follow-up samples of iPD patients or healthy controls. In
the three cases of LRRK2 mutation carriers that we had samples
2 years apart, no difference was found in antibody titer or epitope
mapping of the anti-Snca antibodies. Accordingly, in those ana-
lyzed patients the anti-Snca reactivity seems to be stable. None of
the asymptomatic LRRK2 carriers have been converted to symp-
tomatic along the course of this study. Clearly, further studies are
required to ascertain the changes over time of the anti-Snca anti-
body response and repertoire to be able to ascertain a correlation
of the immune response with PD pathology.
An interesting question is whether the anti-Snca antibody
response is either beneficial or detrimental from the point of view
of onset or progression of PD pathology. Studies in mice have
reported that active immunization with Snca of mice transgenic
for human Snca alleviates the Snca aggregation (Masliah et al.,
2005) being more effective those antibodies directed against the C-
terminal portion of Snca. More recent studies have shown that pas-
sive immunization of those transgenic mice with anti-C-terminal
Snca monoclonal antibodies also alleviates behavioral and neu-
ropathological deficits of the transgenic mice model (Masliah et al.,
2011). Taking into account those results, it could be predicted that
human subjects with anti-C-terminal Snca antibodies would be
somehow “protected” in comparison to those individuals whose
anti-Snca antibodies main epitope was located in other regions of
Snca or have no antibodies. With the limited number of patients
found in this study to have anti-C-terminal antibodies (11 individ-
uals from a total of 21 positive) no such “protection” was evident
by analyzing the possible correlation with different parameters
including age, sex, years of disease evolution, or the disability score
of PD (H&Y or the UPDRS). Furthermore, anti-C-terminal anti-
bodies are the main class present in healthy control subjects, and
as a consequence they may reflect a lost of self-tolerance as a part
of the development of an autoimmune mechanism totally unre-
lated to PD pathology. Clearly, more extensive number of patients
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and healthy controls are needed to clarify the role of anti-Snca
antibodies.
The presence of circulating anti-Snca antibodies has a clear
tendency to cluster in certain families carrying the LRRK2 muta-
tion, indicating that a genetic (or common environmental) factor
could be implicated in the production of those antibodies in
human subjects. Epitope mapping has demonstrated the absence
of anti-N-terminal (a.a. 1–60) anti-Snca antibodies in positive
healthy controls and the predominance of anti-N and C-terminal
antibodies in LRRK2 mutation carriers and iPD patients, being
N122 a key residue for recognition by the C-terminal directed
human anti-Snca antibodies. Further familial cohort studies, not
simple case-control studies, may allow ascertaining the possible
existence of an anti-Snca (auto) immune response in humans
and clarifying if there is some relationship between the anti-
Snca reactivity and PD onset or progression. Finally, this type
of studies may also provide some direct basis for the use of an
immunological intervention for the treatment of PD and other
synucleinopathies.
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